Compare Adaptive Biotechnologies Corp (ADPT) vs Amplify Transformational Data Sharing ETF (BLOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Amplify Transformational Data Sharing ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.47 (market cap $4.04B), while Amplify Transformational Data Sharing ETF trades at $60.12. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Amplify Transformational Data Sharing ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | BLOK | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | — |
52-Week High | $25.45 | $74.10 |
52-Week Low | $12.30 | $47.36 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
BLOK trades at $60.12, up 1.76% with a bearish technical signal from moving averages but neutral oscillators. Support lies at $59 and resistance at $61. The ETF's financial ratios are not disclosed, and a small dividend of $0.08 is scheduled for June 2026. Recent news highlights institutional trimming and focus on AI infrastructure holdings.
Outlook remains cautious due to bearish technicals and lack of fundamental data. Risks include sector volatility and institutional selling. Opportunities may arise from AI-driven growth in portfolio companies, but investors should await clearer financial metrics for valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Amplify Transformational Data Sharing ETF
The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →
